Page 19 - Patrick Wingrove News Today

Bristol Myers Squibb on Friday sued the US government in an attempt to halt the Medicare drug price negotiation program that analysts believe will involve one of its top-selling medicines.

By Patrick Wingrove (Reuters) - Bristol Myers Squibb Co on Friday sued the U.S. government in an attempt to halt the Medicare drug price negotiation p...

Bristol Myers Squibb Co on Friday sued the U.S. government in an attempt to halt the Medicare drug price negotiation program that analysts believe will involve one of its top-selling medicines, saying it violates the Fifth and First Amendments to the U.S. Constitution. This is the third lawsuit so far challenging the law - part of President Joe Biden’s signature Inflation Reduction Act (IRA) - which the pharmaceutical industry says will curtail profits and compel them to pull back on dev...

The Biden administration on Friday announced it would impose inflation penalties on 43 drugs for the third quarter of 2023, having fined 27 earlier this year, in a move it said would lower costs... | June 9, 2023

NEW YORK -Merck & Co sued the U.S. government on Tuesday, seeking to halt the Medicare drug price negotiation program contained in the Inflation Reduction Act , which it argues violates the Fifth... | June 10, 2023

NEW YORK (Reuters) -Merck & Co sued the U.S. government on Tuesday, seeking to halt the Medicare drug price negotiation program contained in the Inflation Reduction Act (IRA), which it argues violates the Fifth and First Amendments to the U.S. Constitution. This is the first attempt by a drugmaker to challenge the law, which the pharmaceutical industry says will result in a loss of profits that will force them to pull back on developing groundbreaking new treatments. The Biden administration...

Johnson & Johnsons legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the drug a larger contributor to... | June 5, 2023

(Reuters) - Some of the world's biggest drugmakers are laying legal groundwork to fight the U.S. plan to negotiate drug prices for its Medicare health coverage, including the argument that a ban against speaking about these talks violates constitutional rights, according to six industry sources. | 06:17am

Moderna Inc on Thursday reported stronger-than-expected sales of $1.9 billion for its COVID-19 vaccine in the first quarter, driven by a surge of revenue deferred from 2022, but left its 2023... | May 4, 2023

Novavax Inc cut about $50 million in costs in the first quarter of 2023 and plans to slash more, Chief Executive John Jacobs said in an interview on Wednesday.... | April 12, 2023